Brazilian health authorities are sounding the alarm over a surge in illicit weight‑loss medications entering the country from Paraguay. According to CNN Brasil, these products—often marketed as “canetas” (pens) containing tirzepatide or similar GLP‑1 analogues—are sold without refrigeration, quality controls, or sanitary registration, exposing consumers to dangers ranging from pancreatitis and severe hypoglycemia to long‑term autoimmune reactions.
Health risks amplified by poor storage
Experts warn that the active molecules in these pens are extremely temperature‑sensitive. The Sociedade Brasileira de Endocrinologia notes that exposure to heat can degrade the peptide, reducing efficacy or turning it into a potential immunogenic agent. Dr. Clarissa Rios, a sports medicine and nutrology specialist, told CNN Brasil that users may unknowingly ingest wildly variable doses, risking acute complications such as pancreatitis, hepatic injury, or dangerous blood‑pressure swings.
A booming illegal trade
Data from the Receita Federal shows the scale of the problem: between January and May 2025, seized weight‑loss products totaled just over R$2.3 million. In the same period of 2026, that figure jumped to more than R$47.3 million—a twentyfold increase. The contraband is frequently concealed in vehicle parts, shoes, or tires, exploiting the warm climate along the Brazil‑Paraguay frontier to evade detection. Under Brazilian law, smuggling unregistered medicines is a crime against public health punishable by 10 to 15 years in prison.
Regulatory gaps and binational response
While Paraguay’s drug authority, Dinavisa, has approved some tirzepatide products for local use, Brazilian regulators (Anvisa) have not cleared them for import. A legal loophole allows individuals to bring small quantities for personal use, a provision that traffickers exploit. In response, Anvisa and Dinavisa recently signed a memorandum of understanding to strengthen cooperation on monitoring falsified medicines and improving regulatory alignment, though critics argue that Dinavisa’s approval standards remain weaker than those of Anvisa, the FDA, or the EMA.
What users should know
Anvisa stresses that any GLP‑1 medication must be kept between 2 °C and 8 °C before and after treatment begins. The agency advises consumers to obtain weight‑loss drugs only through licensed pharmacies with valid prescriptions and to report suspicious offers to health authorities. As the informal market continues to grow, officials urge the public to prioritize safety over the promise of rapid weight loss.